

**Appendix A**  
**Currently Pending Claims (U.S.S.N. 09/313,299)**

40. (Amended) A method for stimulating the tyrosine phosphorylation of a Flt4 tyrosine kinase receptor in a Flt4-expressing cell, comprising contacting the cell with a composition comprising a polypeptide comprising the amino acid residues 21 to 49 of SEQ ID NO:3, in an amount effective to stimulate the tyrosine phosphorylation of said Flt4 tyrosine kinase receptor.
41. The method of claim 40, wherein the polypeptide comprises the amino acid residues 1 to 49 of SEQ ID NO:3.
42. The method of claim 40, wherein the polypeptide comprises the amino acid residues 21 to 157 of SEQ ID NO:3.
43. The method of claim 40, wherein the polypeptide comprises the amino acid residues 1 to 157 of SEQ ID NO:3.
44. The method of claim 40, wherein the polypeptide comprises the amino acid residues 21 to 419 of SEQ ID NO:3.
45. The method of claim 40, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:3.
46. The method of claim 40, wherein the Flt4-expressing cell is *in vitro*.
47. The method of claim 40, wherein the Flt4-expressing cell is *in vivo*.
48. The method of claim 47, wherein the Flt4-expressing cell is an endothelial cell.
49. The method of claim 48, wherein the endothelial cell is in lymphatic endothelia.
50. A method for promoting growth of endothelial cells that express the flt4 tyrosine kinase receptor, comprising contacting the cells with a polypeptide comprising the amino acid residues 21 to 49 of SEQ ID NO:3, in an amount effective to promote the growth of the endothelial cells.
51. The method of claim 50, wherein the polypeptide comprises the amino acid residues 1 to 49 of SEQ ID NO:3.

52. The method of claim 50, wherein the polypeptide comprises the amino acid residues 21 to 157 of SEQ ID NO:3.
53. The method of claim 50, wherein the polypeptide comprises the amino acid residues 1 to 157 of SEQ ID NO:3.
54. The method of claim 50, wherein the polypeptide comprises the amino acid residues 21 to 419 of SEQ ID NO:3.
55. The method of claim 50, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:3.
56. The method of claim 50, wherein the endothelial cells are *in vivo*.
57. The method of claim 56, wherein the endothelial cells are in lymphatic endothelia.